Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S. Steelman, James A. McCubrey, Agostino Tafuri et al.|Aging|2011Cited by 707
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human HealthWilliam H. Chappell, James A. McCubrey, Linda S. Steelman et al.|Oncotarget|2011Cited by 579
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome ResistanceJames A. McCubrey, Alberto M. Martelli, Linda S. Steelman et al.|Oncotarget|2012Cited by 317
Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.James A. McCubrey, Alberto M. Martelli, Linda S. Steelman et al.|Oncotarget|2012Cited by 307
Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cellsMarco Donia, Ferdinando Nicoletti, Katia Mangano et al.|Journal of Autoimmunity|2009Cited by 77